Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.

Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, Okamoto Y, Torii K, Noda S.

Hum Cell. 2009 Nov;22(4):101-6. doi: 10.1111/j.1749-0774.2009.00075.x.

PMID:
19874399
2.

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.

Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, Wake N.

Oncol Rep. 2013 Jul;30(1):25-34. doi: 10.3892/or.2013.2433.

3.

Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer.

Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, Okamoto Y, Torii K, Noda S.

Hum Cell. 2009 May;22(2):49-54. doi: 10.1111/j.1749-0774.2009.00068.x.

PMID:
19379464
4.

Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.

Yu H, Huang YJ, Liu Z, Wang LE, Li G, Sturgis EM, Johnson DG, Wei Q.

Mol Carcinog. 2011 Sep;50(9):697-706. doi: 10.1002/mc.20806.

5.

Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.

Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC, Lee YJ.

Oncol Rep. 2011 Jun;25(6):1755-63. doi: 10.3892/or.2011.1254.

PMID:
21479369
6.

Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

Walsh CS, Miller CW, Karlan BY, Koeffler HP.

Gynecol Oncol. 2007 Mar;104(3):660-4.

PMID:
17123590
7.

Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.

Singhal P, Hussain S, Thakur N, Batra S, Salhan S, Bhambani S, Bharadwaj M.

DNA Cell Biol. 2013 Jan;32(1):19-27. doi: 10.1089/dna.2012.1718.

PMID:
23210739
8.
9.

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.

Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.

Clin Cancer Res. 2007 Jul 15;13(14):4123-9.

10.

Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.

Chien WP, Wong RH, Cheng YW, Chen CY, Lee H.

Ann Surg Oncol. 2010 Apr;17(4):1194-202. doi: 10.1245/s10434-009-0853-2.

PMID:
19941079
11.

Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.

Xiong X, Wang M, Wang L, Liu J, Zhao X, Tian Z, Wang J.

Leuk Res. 2009 Nov;33(11):1454-8. doi: 10.1016/j.leukres.2009.04.007.

PMID:
19423162
12.

Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.

Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A.

BMC Cancer. 2010 Mar 10;10:88. doi: 10.1186/1471-2407-10-88.

13.

[Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].

Liu JN, Zhang XM, Guo YL, Sun T, Lin DX, Wen T.

Zhonghua Zhong Liu Za Zhi. 2008 May;30(5):335-8. Chinese.

PMID:
18953830
14.

TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study.

Joshi AM, Budhathoki S, Ohnaka K, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Maekawa T, Yasunami Y.

Jpn J Clin Oncol. 2011 Feb;41(2):232-8. doi: 10.1093/jjco/hyq200.

PMID:
21051533
15.

Effects of p53 codon 72 and MDM2 SNP309 polymorphisms on gastric cancer risk among the Iranian population.

Moradi MT, Salehi Z, Aminian K, Yazdanbod A.

Asian Pac J Cancer Prev. 2014;15(17):7413-7.

16.

Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.

Qiu M, Liu Y, Yu X, Qin L, Bei C, Zeng X, Qiu X, Tang B, He S, Yu H.

Tumour Biol. 2016 Mar;37(3):3863-70. doi: 10.1007/s13277-015-4222-4.

PMID:
26476535
17.
18.

MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population.

Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z, Sabapathy K.

Carcinogenesis. 2008 Apr;29(4):754-61. doi: 10.1093/carcin/bgn024.

PMID:
18281248
19.

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women.

Zając A, Smolarz B, Stachowiak G, Wilczyński JR.

Med Oncol. 2014 Nov;31(11):286. doi: 10.1007/s12032-014-0286-z.

20.

MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.

Akkiz H, Sümbül AT, Bayram S, Bekar A, Akgöllü E.

Cancer Epidemiol. 2010 Aug;34(4):448-52. doi: 10.1016/j.canep.2010.04.008.

PMID:
20447891
Items per page

Supplemental Content

Support Center